PROTAC collaboration with Boehringer Ingelheim (AC-BI Team)

PROTAC collaboration with Boehringer Ingelheim

The AC-BI collaboration team is a multi-disciplinary team which was formally established in 2016, bringing together our expertise in targeted protein degradation with Boehringer Ingelheim’s expertise in Drug Discovery and clinical development of new therapeutic agents. They are focussed on translating fundamental academic discoveries for the benefit of cancer patients through the development of proteolysis targeting chimeras (PROTACs). The team’s structure-guided approach has allowed them to drug previously “undruggable” cancer targets, leading to the development of highly selective and potent first-in-class PROTACs against proteins such as SMARCA2 and KRAS.